Psychological burden of psoriatic patients in a German university hospital dermatology department.
Patient Health Questionnaire
Short Form Health Survey-36
depression
psoriasis
psychological burden
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
29
10
2020
received:
25
08
2020
accepted:
16
11
2020
pubmed:
24
12
2020
medline:
3
6
2021
entrez:
23
12
2020
Statut:
ppublish
Résumé
Psoriasis has a strong impact on patients' lives and is closely linked to psychiatric disorders such as depression, anxiety and substance-related disorders, especially dependence on alcohol and nicotine. The aim of our study was to systematically assess the psychiatric comorbidity and possible associations between psychological factors, disease severity and dermatology-related quality of life in psoriatic patients from a high-need university hospital dermatology department. Consecutive psoriatic patients (new and permanent patients) at the Department of Dermatology, University Hospital Essen, Germany, were asked to fill out a paper-based questionnaire. In the first part of the questionnaire, baseline demographics, pre-existing mental disorders and data on substance abuse were collected. In the second part of the questionnaire, mental and physical health was explored using different validated self-rating tests. The current Psoriasis Area and Severity Index (PASI) was documented by a dermatologist. Patients with signs of mental disorders were offered an appointment with a board-certified psychiatrist. Between August 2016 and February 2019, 228 consecutive psoriatic patients (138 men [60.5%], 90 women [39.5%]; mean age, 48.3 years [standard deviation, 13.6; range, 18-80]) participated in the study. Approximately 50% of the patients had evidence of suffering from mental health problems, mostly depression and anxiety, as well as alcohol dependence. Patients with a PASI of 3 or more showed a statistically significant reduced Dermatology Life Quality Index (DLQI) and a significantly impaired psychological as well as physical quality of life. DLQI correlated with all psychological test results. The data indicate a significant psychological burden in a tertiary psoriatic population. Our findings underscore the importance of screening psoriatic patients for psychiatric disorders, with a focus on depression, anxiety as well as alcohol and nicotine dependence, in a multidimensional approach involving psychiatrists and psychologists.
Identifiants
pubmed: 33354818
doi: 10.1111/1346-8138.15721
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
794-806Informations de copyright
© 2020 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147-51.
Schafer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M. Epidemiology of psoriasis in Germany-analysis of secondary health insurance data. Gesundheitswesen. 2011;73:308-13.
Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303-7.
Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol. 2014;23:705-9.
Patel N, Nadkarni A, Cardwell LA, Vera N, Frey C, Patel N, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18:613-20.
Koo J, Marangell LB, Nakamura M,Armstrong A, Jeon C, Bhutani T, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31:1999-2009.
Tribo MJ, Turroja M, Castano-Vinyals G, Bulbena A, Ros E, García-Martínez P, et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish Individuals with Psoriasis. Acta Derm Venereol. 2019;99:417-22.
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891-5.
Brenaut E, Horreau C, Pouplard C, Barnetche T, Paul C, Richard MA, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):30-5.
Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology. 2010;220:38-43.
Zink A, Herrmann M, Fischer T, Lauffer F, Garzorz-Stark N, Böhner A, et al. Addiction: an underestimated problem in psoriasis health care. J Eur Acad Dermatol Venereol. 2017;31:1308-15.
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.
Fitz L, Zhang W, Soderstrom C, Fraser S, Lee J, Quazi A, et al. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis. Clin Exp Dermatol. 2018;43:790-7.
Kinahan CE, Mazloom S, Fernandez AP. Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study. Br J Dermatol. 2015;172:428-36.
Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29:487-95.
Connor CJ, Liu V, Fiedorowicz JG. Exploring the physiological link between psoriasis and mood disorders. Dermatol Res Pract. 2015; 2015: 409637.
Breuer K, Goldner FM, Jager B, Werfel T, Schmid-Ott G. Chronic stress experience and burnout syndrome have appreciable influence on health-related quality of life in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1898-904.
Leonard BE. Inflammation and depression: a causal or coincidental link to the pathophysiology? Acta Neuropsychiatr. 2018;30:1-16.
Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev. 2014;66:80-101.
Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev. 2018;98:477-504.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22-34.
Nadeem A, Ahmad SF, Al-Harbi NO, Fardan AS, El-Sherbeeny AM, Ibrahim KE, et al. IL-17A causes depression-like symptoms via NFkappaB and p38MAPK signaling pathways in mice: implications for psoriasis associated depression. Cytokine. 2017;97:14-24.
Farkas A, Kemeny L. Alcohol, liver, systemic inflammation and skin: a focus on patients with psoriasis. Skin Pharmacol Physiol. 2013;26:119-26.
McAleer MA, Mason DL, Cunningham S, O’Shea S, McCormick PA, Stone C, et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol. 2011;164:1256-61.
Zhu KJ, Zhu CY, Fan YM. Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J Dermatol. 2012;39:770-3.
Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CE. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol. 2008;158:138-40.
Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol. 1994;130:473-7.
Parisi R, Webb RT, Carr MJ, Moriarty KJ, Kleyn CE, Griffiths CEM, et al. Alcohol-related mortality in patients with psoriasis: a population-based cohort study. JAMA Dermatol. 2017;153:1256-62.
Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol. 2011;165:1162-8.
Fortes C, Mastroeni S, Leffondre K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580-84.
Lim DS, Bewley A, Oon HH. Psychological profile of patients with psoriasis. Ann Acad Med Singapore. 2018;47 516-22.
Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol. 2017;176:1028-34.
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135:984-91.
Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47:37-45.
Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US Population: National Health and Nutrition Examination Survey 2009-2012. JAMA Dermatol. 2016;152:73-9.
Ng CY, Yang YW, Liu SH, Rachel Lu J-F, Yang L-C, Yang L-C, et al. SF-36 healty survey on psoriasis quality-of-life: a study of 414 Taiwanese patients. J Dermatol. 2015;42:159-65.
Al-Jefri K, Newbury-Birch D, Muirhead CR,Gilvarry E, Araújo-Soares V, Reynolds NJ, et al. High prevalence of alcohol use disorders in patients with inflammatory skin diseases. Br J Dermatol. 2017;177:837-44.
Higgins-Biddle JC, Babor TF. A review of the Alcohol Use Disorders Identification Test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: past issues and future directions. Am J Drug Alcohol Abuse. 2018;44:578-86.
Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol. 2008;47:1019-23.
Gsellhofer BFE, Weiler D, Vogt M, Hron U, Platt J.European Addiction Severity Index EuropASI. German version, according to the American original version by T. McLellan, 5. Ed., 1992 and the European version EuropASI by A. Kokkevi, Ch. Hartgers, P. Blanken, E.-M. Fahrner, G. Pozzi, E. Tempesta, A. Uchtenhagen, 1993, in the version dated 3rd May 1997; http://www.emcdda.europa.eu/attachements.cfm/att_23587_DE_ASI_FB_deutsch%20060629%20final.pdf; Accessed 27Apr 2020 1993.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.
Kroenke K, Spitzer RL, Williams JB, Lowe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010;32:345-59.
Löwe B, Spitzer R, Zipfel S, Herzog W. Manual Komplettversion und Kurzform autorisierte deutsche Version des “Prime MD Patient Health Questionnaire (PHQ)”.
Bullinger M, Blome C, Sommer R, Lohrberg D, Augustin M. Health-related quality of life: a pivotal endpoint in benefit assessment of medical procedures. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015;58:283-90.
Williams N. The AUDIT questionnaire. Occup Med (Lond). 2014;64:308.
Moore BL, Schneider JA, Ryan JJ. Fagerstrom’s Tolerance Questionnaire: clarification of item and scoring ambiguities. Addict Behav. 1987; 12: 67-8.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119-27.
Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989;12:159-82.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-7.
Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract. 2010;16:574-9.
Gerdes S, Korber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatolog Treat. 2020;31:470-5.
Kiedrowski R, Dirschka T, Krähn-Senftleben G, Ostendorf R, Quist SR, Reinhold U, et al.Empfehlungen für die ambulante Versorgung von Psoriasis vulgaris- Aktualisierter praxisnaher Behandlungspfad. 2019.
Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040-7.
Bangemann K, Schulz W, Wohlleben J, Weyergraf A, Snitjer I, Werfel T, et al. Depression and anxiety disorders among psoriasis patients: protective and exacerbating factors. Hautarzt. 2014;65:1056-61.
Korman AM, Hill D, Alikhan A, Feldman SR. Impact and management of depression in psoriasis patients. Expert Opin Pharmacother. 2016;17:147-52.
Jin W, Zhang S, Duan Y. Depression symptoms predict worse clinical response to etanercept treatment in psoriasis patients. Dermatology. 2019;235:55-64.
Lebowitz E, Lebwohl M. Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs. SKIN J Cutan Med. 2019;3:72-81.
Wittenberg GM, Stylianou A, Zhang Y, Sun Y, Gupta A, Jagannatha PS, et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol Psychiatry. 2020;25:1275-1285.
Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016; 175:273-86.
Tobin AM, Higgins EM, Norris S, Kirby B. Prevalence of psoriasis in patients with alcoholic liver disease. Clin Exp Dermatol. 2009;34:698-701.
Sondermann W, Djeudeu Deudjui DA, Körber A, Slomiany U, Brinker TJ, Erbel R, et al. Psoriasis, cardiovascular risk factors and metabolic disorders: sex-specific findings of a population-based study. J Eur Acad Dermatol Venereol. 2020;34:779-86.
Skinner HA. The drug abuse screening test. Addict Behav. 1982;7:363-71.
Burden AD, Hilton Boon M, Leman J, Wilson H, Richmond R, Ormerod AD. Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. BMJ. 2010;341:c5623.
Radtke MA, Mrowietz U, Feuerhahn J, Härter M, von Kiedrowski R, Nast A, et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. J Dtsch Dermatol Ges. 2015;13:674-90.
Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252:1905-7.
Davidovici BB, Sattar N, Prinz J et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
Brinker TJ, Enk A, Gatzka M, Nakamura Y, Sondermann W, Joachim Omlor A, et al. A dermatologist’s ammunition in the war against smoking: a photoaging app. J Med Internet Res. 2017;19:e326.
Naldi L. Lifestyle intervention should be an essential component of medical care for skin disease: a challenging task. Br J Dermatol. 2014;171:934-5.